Dermapharm Holding SE
DMPHF
$38.50
-$2.12-5.23%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.35% | -1.83% | 6.68% | 10.58% | 5.34% |
| Total Other Revenue | -- | -- | 75.14% | -- | -- |
| Total Revenue | 2.35% | -1.83% | 6.79% | 10.58% | 5.34% |
| Cost of Revenue | -8.68% | 0.60% | 4.24% | 6.30% | -5.26% |
| Gross Profit | 8.88% | -3.07% | 8.60% | 13.33% | 12.80% |
| SG&A Expenses | 7.66% | 5.49% | 5.22% | 2.11% | 10.60% |
| Depreciation & Amortization | -9.89% | -1.94% | -5.67% | 1.07% | -31.37% |
| Other Operating Expenses | -0.51% | -9.53% | 858.03% | 8.73% | 6.90% |
| Total Operating Expenses | -2.40% | -0.41% | 5.67% | 5.20% | -2.40% |
| Operating Income | 44.98% | -7.85% | 10.21% | 40.59% | 265.75% |
| Income Before Tax | 28.01% | -24.61% | 694.14% | 35.80% | 1,009.11% |
| Income Tax Expenses | 23.33% | -23.19% | 100.05% | 34.64% | 49.74% |
| Earnings from Continuing Operations | 30.78% | -25.29% | 660.51% | 36.31% | 275.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -99.49% | -62.94% | 115.28% | -167.58% | 41.79% |
| Net Income | 27.58% | -25.76% | 853.75% | 31.69% | 285.86% |
| EBIT | 44.98% | -7.85% | 10.21% | 40.59% | 265.75% |
| EBITDA | 22.96% | -6.25% | 9.70% | 28.06% | 21.22% |
| EPS Basic | 28.51% | -25.79% | 859.40% | 31.87% | 286.16% |
| Normalized Basic EPS | 25.79% | -25.16% | 210.15% | 30.85% | 1,215.31% |
| EPS Diluted | 28.51% | -25.79% | 859.40% | 31.87% | 286.16% |
| Normalized Diluted EPS | 25.79% | -25.16% | 210.15% | 30.85% | 1,215.31% |
| Average Basic Shares Outstanding | -0.72% | 0.05% | -0.82% | -0.13% | -0.15% |
| Average Diluted Shares Outstanding | -0.72% | 0.05% | -0.82% | -0.13% | -0.15% |
| Dividend Per Share | -- | -- | 1.27% | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |